Neoadjuvant therapy in thyroid cancer: an emerging approach
- 16 September 2026
- journal article
- editorial
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 302
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Anaplastic thyroid carcinoma in Argentina: real-world diagnostic lags and treatment barriersEndocrine, 2026
- Integrating antibody–drug conjugates, multispecific antibodies, targeted protein degradation and nanomedicine in precision oncologyJournal of Drug Targeting, 2026
- CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to EfficacyHematological Oncology, 2026
- Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT ‐Based Selection and Outcomes From a 23‐Patient CohortHead & Neck, 2026
- Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experienceHead & Neck, 2024
- Exploring the next generation of antibody–drug conjugatesNature Reviews Clinical Oncology, 2024
- Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF V600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort StudyThyroid®, 2023
- Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case SeriesThyroid®, 2023
- American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentHead & Neck, 2022
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
BRAF
V600E
-Mutated Anaplastic Thyroid CarcinomaThyroid®, 2019